<DOC>
	<DOCNO>NCT00578786</DOCNO>
	<brief_summary>AMB-320/321-E design provide long-term , control monitoring pulmonary arterial hypertension ( PAH ) patient treat ambrisentan ( AMB ) order properly define adverse event profile associate endothelin receptor antagonist ( ERA ) , include incidence severity elevate serum liver function test ( LFTs ) . In addition , study continue efficacy assessment previous study , examine long-term AMB treatment success , compare long-term survival subject treat AMB NIH registry patient PAH .</brief_summary>
	<brief_title>A Long Term Study Ambrisentan Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 ( NCT00423748 ) AMB-321 ( NCT00423202 )</brief_title>
	<detailed_description>AMB-320 ( ARIES-1 ; NCT00423748 ) AMB-321 ( ARIES-2 ; NCT00423202 ) 12-week , Phase 3 , randomize , double-blind , placebo-controlled , multicenter , efficacy study AMB subject PAH . The objective study determine effect three dos AMB ( 2.5 , 5.0 , 10.0 mg ) exercise capacity , well several clinical measure PAH . The current study ( NCT00578786 ) unblinded ( design ) prior completion . The ARIES study identical except dose group assess geographic location study conduct . Both study evaluate placebo 5.0-mg AMB dose group ; however , AMB-320 ( NCT00423748 ) also examine AMB dose 10.0 mg , AMB-321 ( NCT00423202 ) include AMB dose 2.5 mg. AMB-320/321-E optional study subject participate AMB-320 ( NCT00423748 ) AMB-321 ( NCT00423202 ) allow continued long-term treatment AMB .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>1 . Subject must complete Week 12 AMB320 ( NCT00423748 ) AMB321 ( NCT00423202 ) must receive placebo AMB320 ( NCT00423748 ) AMB321 ( NCT00423202 ) meet two early escape criterion ; 2 . Subject must competent understand information give Institutional Review Board ( IRB ) Independent Ethics Committee ( IEC ) approve informed consent form must sign form prior initiation study procedure . 3 . Female subject childbearing potential must agree use two reliable method contraception study completion least four week follow final study visit . Reliable method include : birth control pills/implants/injections , intrauterine device ( IUDs ) , spermicide , diaphragm , condom . Subjects must meet exclusion criterion AMB320 ( NCT00423748 ) AMB321 ( NCT00423202 ) study . In addition , subject meet one follow criterion ineligible participation study : 1 . Subject receive bosentan , sildenafil , iv inotropes time within four week prior AMB320/321E Screening/Randomization Visit ; 2 . Subject receive chronic prostanoid therapy ( epoprostenol , treprostinil , iloprost , beraprost , investigational prostacyclin derivative ) within four week prior AMB320/321E Screening/RandomizationVisit ; 3 . Female subject pregnant breastfeeding ; 4 . Subject cardiovascular , liver , renal , hematologic , gastrointestinal , immunologic , endocrine , metabolic , central nervous system disease , opinion Investigator , may adversely affect safety subject and/or efficacy study drug severely limit lifespan subject ; 5 . Subject demonstrate noncompliance previous medical regimen ; 6 . Subject recent history abuse alcohol illicit drug ; 7 . Subject participate clinical study involve another investigational drug device time within four week prior AMB320/321E Screening/Randomization Visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>